Laura Angelats

CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition

Irene Andreu-Saumell, Alba Rodríguez-García, Vanessa Mühlgrabner et al. · Nature Communications · 2024 · 60 citations · Full text

Life Sciences, Immunology, Oncology +17

Unlocking the potential of engineered immune cell therapy for solid tumors

Víctor Albarrán, Laura Angelats, Julio Delgado et al. · Nature Communications · 2025 · 27 citations · Full text

Life Sciences, Immunology, Oncology +17

HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1

Fara Brasó‐Maristany, Gaia Griguolo, Núria Chic et al. · JNCI Journal of the National Cancer Institute · 2022 · 25 citations · Full text

Medicine, Oncology, Pharmacology +15

Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study

Javier Garciá Corbacho, Alberto Indacochea, Azucena E. González Navarro et al. · Cancer Immunology Immunotherapy · 2023 · 19 citations · Full text

Medicine, Immunology, Oncology +17

A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies

Benedetta Conte, Fara Brasó‐Maristany, Tomás Pascual et al. · EBioMedicine · 2024 · 18 citations · Full text

Medicine, Immunology, Oncology +17